A study comparing two herbal medicines for knee pain and stiffness relief

A randomized open label control clinical study to evaluate the safety and efficacy of painshunya juice in the management of janusandhigat vata with special reference to osteoarthritis. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/112327

Enrollment

Registered

2026-06-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults of either gender between 30 and 70 years of age. 2. Patients presenting with chronic knee joint pain and stiffness of at least 3 months duration, aggravated by walking, bending or occupational activity, with radiological evidence of knee joint degeneration on X-ray knee Grade 1 and Grade 2.

Exclusion criteria

Exclusion criteria: 1. Individuals with recent knee fractures, ligament injuries or other acute knee trauma requiring immediate surgical intervention. 2. Individuals with severe autoimmune disorders such as systemic lupus erythematosus or advanced rheumatoid arthritis with organ involvement, or advanced renal, hepatic or cardiac failure. 3. Participants with uncontrolled hypertension, diabetes mellitus, or major liver or kidney disorders. 4. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Change in knee joint pain, stiffness and physical function assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Timepoint: Baseline, Week 4, Week 8, Week 12 and Week 16	—

Secondary

Measure	Time frame
Change in knee joint pain intensity measured using the Visual Analogue Scale (VAS)Timepoint: Baseline, Week 4, Week 8, Week 12 and Week 16;Change in knee joint range of motion assessed by goniometryTimepoint: Baseline, Week 4, Week 8, Week 12 and Week 16;Change in inflammatory markers Erythrocyte Sedimentation Rate (ESR) and C reactive Protein (CRP)Timepoint: Baseline and Week 12;Safety and tolerability assessed by monitoring of adverse events and laboratory parameters including Complete Blood Count, Liver Function Tests and Kidney Function TestsTimepoint: Baseline and Week 12	—

Measure

Time frame

Change in knee joint pain intensity measured using the Visual Analogue Scale (VAS)Timepoint: Baseline, Week 4, Week 8, Week 12 and Week 16;Change in knee joint range of motion assessed by goniometryTimepoint: Baseline, Week 4, Week 8, Week 12 and Week 16;Change in inflammatory markers Erythrocyte Sedimentation Rate (ESR) and C reactive Protein (CRP)Timepoint: Baseline and Week 12;Safety and tolerability assessed by monitoring of adverse events and laboratory parameters including Complete Blood Count, Liver Function Tests and Kidney Function TestsTimepoint: Baseline and Week 12

—

Countries

India

Contacts

Public ContactDr Sangeeta H Toshikhane

Parul Institute of Ayurveda, Parul University

sangeeta.toshikhane26791@paruluniversity.ac.in9964596479

Outcome results